Clinical Trial Update: Low-Intensity Chemotherapy and Blinatumomab in Treating Patients With Philadelphia Chromosome Negative Relapsed or Refractory Acute Lymphoblastic Leukemia [Phase 2]

View source ↗

Summary

Phase 2 trial update on low-intensity chemotherapy combined with blinatumomab in Philadelphia chromosome–negative relapsed or refractory acute lymphoblastic leu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Blinatumomab (blinatumomab)
• low-intensity chemotherapy (unspecified)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2022-11-04